Reported Sunday, Abbott’s TECTONIC Trial Of Investigational SonicForce Coronary IVL System Meets Primary Safety And Effectiveness Endpoints, With 0.3% 30-Day Target Lesion Failure And 97% Procedural Success In 335 Patient

Benzinga

2026.11.02 06:39 (GMT+0)

Benzingaで開く